Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
Gain Therapeutics (Nasdaq: GANX) has announced an upcoming oral poster presentation at the IAPRD 30th World Congress on Parkinson's Disease and Related Disorders. The event will take place from May 7th-10th in New York City.
The presentation will focus on GT-02287, the company's clinical-stage allosteric GCase modulator designed for treating Parkinson's Disease. Dr. Joanne Taylor, Senior Vice President of Research at Gain Therapeutics, will present findings demonstrating how GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+.
The presentation is scheduled for Saturday, May 10, 2025, during the Guided Poster Tour session from 8:00-9:00 a.m. EST. This showcase highlights Gain's progress in developing next-generation allosteric small molecule therapies.
Gain Therapeutics (Nasdaq: GANX) ha annunciato una prossima presentazione orale con poster al 30° Congresso Mondiale IAPRD sulla Malattia di Parkinson e Disturbi Correlati. L'evento si terrà dal 7 al 10 maggio a New York City.
La presentazione sarà incentrata su GT-02287, il modulatore allosterico GCase in fase clinica dell'azienda, progettato per il trattamento della Malattia di Parkinson. La Dott.ssa Joanne Taylor, Vicepresidente Senior della Ricerca presso Gain Therapeutics, presenterà i risultati che dimostrano come GT-02287 protegga i neuroni dopaminergici dal tossico mitocondriale MPP+.
La presentazione è prevista per sabato 10 maggio 2025, durante la sessione Guided Poster Tour dalle 8:00 alle 9:00 EST. Questo evento mette in luce i progressi di Gain nello sviluppo di terapie allosteriche di piccole molecole di nuova generazione.
Gain Therapeutics (Nasdaq: GANX) ha anunciado una próxima presentación oral con póster en el 30º Congreso Mundial IAPRD sobre la Enfermedad de Parkinson y Trastornos Relacionados. El evento se llevará a cabo del 7 al 10 de mayo en la ciudad de Nueva York.
La presentación se centrará en GT-02287, el modulador alostérico de GCase en fase clínica de la compañía, diseñado para tratar la Enfermedad de Parkinson. La Dra. Joanne Taylor, Vicepresidenta Senior de Investigación en Gain Therapeutics, presentará hallazgos que demuestran cómo GT-02287 protege las neuronas dopaminérgicas contra la toxina mitocondrial MPP+.
La presentación está programada para el sábado 10 de mayo de 2025, durante la sesión Guided Poster Tour de 8:00 a 9:00 a.m. EST. Esta presentación destaca el progreso de Gain en el desarrollo de terapias alostéricas de pequeñas moléculas de próxima generación.
Gain Therapeutics (나스닥: GANX)는 곧 열리는 IAPRD 제30회 세계 파킨슨병 및 관련 질환 학술대회에서 구두 포스터 발표를 진행할 예정입니다. 행사는 5월 7일부터 10일까지 뉴욕시에서 개최됩니다.
발표는 파킨슨병 치료를 위해 개발된 임상 단계의 알로스테릭 GCase 조절제인 GT-02287에 초점을 맞춥니다. Gain Therapeutics의 연구 부문 수석 부사장인 조앤 테일러 박사가 GT-02287이 미토콘드리아 독소 MPP+로부터 도파민 신경세포를 보호하는 연구 결과를 발표할 예정입니다.
발표는 2025년 5월 10일 토요일 동부 표준시 오전 8시부터 9시까지 Guided Poster Tour 세션에서 진행됩니다. 이번 발표는 Gain이 차세대 알로스테릭 소분자 치료제 개발에서 이룬 진전을 보여줍니다.
Gain Therapeutics (Nasdaq : GANX) a annoncé une prochaine présentation orale avec poster lors du 30e Congrès mondial IAPRD sur la maladie de Parkinson et les troubles associés. L'événement se tiendra du 7 au 10 mai à New York.
La présentation portera sur GT-02287, le modulateur allostérique de GCase en phase clinique développé par la société pour traiter la maladie de Parkinson. Dr Joanne Taylor, vice-présidente senior de la recherche chez Gain Therapeutics, présentera des résultats montrant comment GT-02287 protège les neurones dopaminergiques contre la toxine mitochondriale MPP+.
La présentation est prévue le samedi 10 mai 2025, lors de la session Guided Poster Tour de 8h00 à 9h00 EST. Cette présentation met en lumière les progrès de Gain dans le développement de thérapies allostériques de petites molécules de nouvelle génération.
Gain Therapeutics (Nasdaq: GANX) hat eine bevorstehende mündliche Posterpräsentation auf dem 30. Weltkongress der IAPRD über Parkinson und verwandte Erkrankungen angekündigt. Die Veranstaltung findet vom 7. bis 10. Mai in New York City statt.
Die Präsentation konzentriert sich auf GT-02287, den klinischen allosterischen GCase-Modulator des Unternehmens zur Behandlung der Parkinson-Krankheit. Dr. Joanne Taylor, Senior Vice President für Forschung bei Gain Therapeutics, wird Ergebnisse vorstellen, die zeigen, wie GT-02287 dopaminerge Neuronen vor dem mitochondrialen Toxin MPP+ schützt.
Die Präsentation ist für Samstag, den 10. Mai 2025, während der Guided Poster Tour von 8:00 bis 9:00 Uhr EST geplant. Diese Präsentation hebt die Fortschritte von Gain bei der Entwicklung von allosterischen Kleinmolekültherapien der nächsten Generation hervor.
- Clinical-stage allosteric GCase modulator GT-02287 showing potential for Parkinson's Disease treatment
- Scientific leadership presence at major international conference (IAPRD) indicating strong research positioning
- None.
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.
Details of the oral and poster presentation are as follows:
Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+
Presenter: Joanne Taylor, Ph.D., Senior Vice President of Research, Gain Therapeutics
Session: Oral Poster Presentation – Guided Poster Tour
Session Date: Saturday, May 10, 2025
Session Time: 8:00-9:00 a.m. EST
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting.
Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease.
Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with a >
GT-02287 is currently being evaluated in a Phase 1b clinical trial for the treatment of Parkinson’s disease with or without a GBA1 mutation. The primary endpoint of the trial, which is currently enrolling participants across 7 sites in Australia, is to evaluate the safety and tolerability of GT-02287 after 3 months of dosing in people with Parkinson’s disease.
Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
What is Gain Therapeutics (GANX) presenting at IAPRD 2025 World Congress?
When and where is Gain Therapeutics' IAPRD 2025 presentation?
What is GT-02287 being developed for by Gain Therapeutics?
Who is presenting Gain Therapeutics' research at IAPRD 2025?
What type of therapy is Gain Therapeutics (GANX) developing?
